I will disagree somewhat with your points JG.
It is a gamble - both positive and negative aspects you state are generally in line with what I would expect.
IF this Ebolacide2 gambit pays off as you outline (and as many here suspect) and is a success in the upcoming USAMRIID tests - we could easily see a spike in shareprices that would both make the company look good to additional investors, and allow Flucide (or Denguecide, or HIVcide,....) work to progress with far less need to run dilutive financing like selling stock.
This would also serve as one heck of a good bit of amazing PR for NNVC and for it's virus-treatment development platform.
IF the Ebolacide2 gambit doesn't pay off as you outline then yes - we should expect to see the shareprices here take a short-term hit. We could see shareprices drop down lower than we have seen them drop even at the height of the Pump Terminator hype last Winter/Spring. That would (indeed) impact how further funding (via dilutive share-sales) would have to be done and how dilutive that might be to current shareholders.
Personally - if the 2nd scenario is what we end up with (and I view this as a substantial probability, but not a high likelihood) then I will continue to ride out Flucide development, TOX, and Phase I/II testing - barring bad news on that front as well.
I (in fact) will most likely look to average down when I think NNVC has somewhat bottomed out and add to what I hold if we see Ebolacide2 not come up to expectations, but Flucide progress being made despite the Ebolacide hang-up.
As I said - I don't view (and others will disagree of course) Ebolacide2 as the prize here in the long-term. My eye remains on Flucide as in the long-run that's where the real money is to be made.
